Stryker Corporation (SYK): Today's Featured Health Care Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Stryker Corporation ( SYK) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day down 1%. By the end of trading, Stryker Corporation rose 79 cents (1.5%) to $53.61 on heavy volume. Throughout the day, 4.6 million shares of Stryker Corporation exchanged hands as compared to its average daily volume of 1.9 million shares. The stock ranged in a price between $51.60-$53.74 after having opened the day at $51.70 as compared to the previous trading day's close of $52.82. Other companies within the Health Care sector that increased today were: Given Imaging ( GIVN), up 19.1%, Aegerion Pharmaceuticals ( AEGR), up 9.3%, Oxygen Biotherapeutics ( OXBT), up 9.1%, and AspenBio Pharma ( APPY), up 8.8%.
  • ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.

Stryker Corporation, together with its subsidiaries, operates as a medical technology company. The company operates in three segments: Reconstructive, MedSurg, and Neurotechnology and Spine. Stryker Corporation has a market cap of $20.34 billion and is part of the health services industry. The company has a P/E ratio of 14.7, equal to the average health services industry P/E ratio and below the S&P 500 P/E ratio of 17.7. Shares are up 6.3% year to date as of the close of trading on Wednesday. Currently there are 14 analysts that rate Stryker Corporation a buy, no analysts rate it a sell, and 11 rate it a hold.

TheStreet Ratings rates Stryker Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, growth in earnings per share, increase in net income and reasonable valuation levels. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the negative front, MannKind Corporation ( MNKD), down 24.2%, Align Technology ( ALGN), down 20.4%, CytRx Corporation ( CYTR), down 19.6%, and ImmunoCellular Therapeutics ( IMUC), down 14.1%, were all laggards within the health care sector with Thermo Fisher Scientific ( TMO) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.